{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:ixoberogene soroparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:bevufenogene nofeparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT01436968: Phase 3 Interventional Active, not recruiting Prostate Cancer
(2011)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:rapcabtagene autoleucel [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04105374: Phase 2/Phase 3 Interventional Withdrawn Anaplastic Astrocytoma
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:clemidsogene lanparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04652908: Phase 1/Phase 2 Interventional Recruiting Myelomeningocele
(2021)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04582344: Phase 3 Interventional Completed COVID-19
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:dazagamglogene autogedtemcel [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE